Evidence map›Paper›PMID 41836229›Full record

ArticleFrontiers in oncology2026

Case Report: Somatic

Misa Shogaku, Hiroshi Yamada, Seiji Yamada, Ryota Fujinami, Shigeki Yamada, Motoki Tanikawa, Yusuke Okuno, Mitsuhito Mase

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Misa ShogakuDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hiroshi YamadaDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Seiji YamadaDivision of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan.
Ryota FujinamiDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Shigeki YamadaDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Motoki TanikawaDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yusuke OkunoDepartment of Virology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Mitsuhito MaseDepartment of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neurofibromatosis type 1 (NF1) and vestibular schwannoma are genetically and clinically distinct entities, with vestibular schwannomas classically associated with neurofibromatosis type 2. The occurrence of a vestibular schwannoma in a patient with NF1 is rare, and its underlying molecular mechanism remains unclear. Case presentation: We report a 51-year-old man clinically diagnosed with neurofibromatosis type 1 who developed a unilateral vestibular schwannoma presenting with progressive hearing loss and neurological symptoms. Histopathological examination following surgical resection confirmed the diagnosis of vestibular schwannoma, and genetic analyses were subsequently performed on the schwannoma, a cutaneous neurofibroma, and peripheral blood from the same patient. Genetic findings: Whole-exome sequencing revealed a pathogenic germline NF1 mutation shared across all analyzed samples. In contrast, the vestibular schwannoma harbored a somatic NF2 mutation accompanied by loss of chromosome 22, while these alterations were absent in the neurofibroma and blood samples. Conclusion: This case demonstrates that a vestibular schwannoma arising in a patient with neurofibromatosis type 1 can be driven by secondary somatic NF2 alterations accompanied by loss of chromosome 22. Comprehensive multi-tissue genetic analysis enabled direct distinction between germline and tumor-specific events, highlighting the critical role of tumor-specific somatic alterations beyond the germline background.

Indexed as

germline mutationneurofibromatosis type 1neuro-oncologysomatic mutationvestibular schwannomawhole-exome sequencing

Identifiers

PMID41836229
PMCPMC12979104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.